Trials
10 active
10 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Arm A: AZD0120 - autologous BCMA/CD19 dual-targeting CAR-T cells. Participants will receive lymphodepletion conditioning (cyclophosphamide and fludarabine) followed by AZD0120 CAR-T cell infusion.”In the company’s words, NCT07735637 on ClinicalTrials.gov
- Tested for
- Relapsed Refractory Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Newly Diagnosed Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis, Lupus Erythematosus, Systemic and 6 more
- Main trialPhase 3
- “This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.”In the company’s words, NCT07391657 on ClinicalTrials.gov
- Other names
- GC012F
Other drugs for Relapsed Refractory Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
Coming up9
- 1 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 22 Feb 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 26 May 2028Phase 1 trial completes · ClinicalTrials.gov
- 14 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 2 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
- 12 Dec 2028Phase 1 trial completes · ClinicalTrials.gov
- 11 Jan 2029Phase 3 trial completes · ClinicalTrials.gov
- 1 May 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 15 Aug 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 14 Jun 2028 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) | |
| Phase 3Recruiting | 2 Nov 2028 | A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). | |
| Phase 3Recruiting | 11 Jan 2029 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT | |
| Phase 1/2Recruiting | 1 Oct 2027 | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) | |
| Phase 1/2Recruiting | 22 Feb 2028 | A Study of AZD0120 in Autoimmune Diseases | |
| Phase 1/2Recruiting | 1 May 2029 | A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | |
| Phase 1/2Recruiting | 15 Aug 2029 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | |
| Phase 1Recruiting | 26 May 2028 | A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | |
| Phase 1Recruiting | 12 Dec 2028 | An Open-label Study of AZD0120 in Adults With Multiple Sclerosis | |
| Phase 3Authorised | not given | A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026